Innoviva Inc (NASDAQ:INVA)

14.59
Delayed Data
As of May 18
 -0.07 / -0.48%
Today’s Change
11.47
Today|||52-Week Range
17.99
+2.82%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Other
MARKET CAP
$1.5B

Company Description

Innoviva, Inc. engages in the development, commercialization, and financial management of bio-pharmaceuticals. Its portfolio includes Relvar Breo Ellipta, which is a once-daily combination medicine consisting of a long-acting beta2 agonist, vilanterol, and an inhaled corticosteroid, fluticasone furoate; and Anoro Ellipta, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, LABA, VI. The company was founded by P. Roy Vagelos, Mathai Mammen, and George M. Whitesides in November 1996 and is headquartered in Brisbane, CA.

Contact Information

Innoviva, Inc.
2000 Sierra Point Parkway
Brisbane California 94005
P:(650) 238-9600
Investor Relations:

Employees

Shareholders

Mutual fund holders44.61%
Other institutional28.89%
Individual stakeholders2.81%

Top Executives

Eric d'EsparbesCEO, Chief Financial Officer & Senior VP
Theodore J. WitekChief Scientific Officer & Senior Vice President
George B. AbercrombieChief Commercial Officer & Senior Vice President